KR20170002407A - C형 간염 바이러스의 강력하고 선택적인 저해제 - Google Patents

C형 간염 바이러스의 강력하고 선택적인 저해제 Download PDF

Info

Publication number
KR20170002407A
KR20170002407A KR1020167030815A KR20167030815A KR20170002407A KR 20170002407 A KR20170002407 A KR 20170002407A KR 1020167030815 A KR1020167030815 A KR 1020167030815A KR 20167030815 A KR20167030815 A KR 20167030815A KR 20170002407 A KR20170002407 A KR 20170002407A
Authority
KR
South Korea
Prior art keywords
alkyl
hcv
compound
aryl
substituents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020167030815A
Other languages
English (en)
Korean (ko)
Inventor
스티븐 제이 코츠
리처드 앤서니 휘터커
타마라 로사리오 맥브래이어
준싱 시
프랑크 앙블라르
홍왕 장
룽후 저우
레이먼드 에프 쉬나지
Original Assignee
코크리스탈 파마, 아이엔씨.
에모리 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코크리스탈 파마, 아이엔씨., 에모리 유니버시티 filed Critical 코크리스탈 파마, 아이엔씨.
Publication of KR20170002407A publication Critical patent/KR20170002407A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y10S514/894—

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020167030815A 2014-04-15 2015-04-15 C형 간염 바이러스의 강력하고 선택적인 저해제 Withdrawn KR20170002407A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461980016P 2014-04-15 2014-04-15
US61/980,016 2014-04-15
PCT/US2015/025903 WO2015160907A2 (en) 2014-04-15 2015-04-15 Potent and selective inhibitors of hepatitis c virus

Publications (1)

Publication Number Publication Date
KR20170002407A true KR20170002407A (ko) 2017-01-06

Family

ID=54324704

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167030815A Withdrawn KR20170002407A (ko) 2014-04-15 2015-04-15 C형 간염 바이러스의 강력하고 선택적인 저해제

Country Status (14)

Country Link
US (1) US9926295B2 (enExample)
EP (1) EP3131892A4 (enExample)
JP (1) JP2017513852A (enExample)
KR (1) KR20170002407A (enExample)
CN (1) CN106661004A (enExample)
AU (1) AU2015247706A1 (enExample)
BR (1) BR112016023833A2 (enExample)
CA (1) CA2945514A1 (enExample)
IL (1) IL248318A0 (enExample)
MX (1) MX2016013434A (enExample)
PH (1) PH12016502039A1 (enExample)
RU (1) RU2016144076A (enExample)
SG (1) SG11201608587QA (enExample)
WO (1) WO2015160907A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
JP2016527232A (ja) 2013-07-17 2016-09-08 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｈｃｖの治療に使用するためのビフェニル誘導体を含む組み合わせ
WO2015184644A1 (zh) * 2014-06-06 2015-12-10 爱博新药研发(上海)有限公司 抑制丙肝病毒的化合物、药物组合物及其应用
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN112203652A (zh) * 2018-05-09 2021-01-08 共晶制药公司 用于治疗hcv的组合疗法
CN109456375B (zh) * 2018-12-11 2019-10-22 枣庄学院 一种抑制丙肝病毒的含单糖基杂环类化合物及制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101492672B1 (ko) * 2008-02-13 2015-02-16 브리스톨-마이어스 스큅 컴퍼니 Ｃ형 간염 바이러스 억제제로서의 이미다졸릴 바이페닐 이미다졸
CA2751458C (en) * 2009-02-06 2018-06-05 Rfs Pharma, Llc Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections
US8377980B2 (en) * 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
BR112013004520A2 (pt) * 2010-08-26 2016-06-07 Univ Emory inibidores potentes e seletivos do virus da hepatite c
WO2012048421A1 (en) * 2010-10-14 2012-04-19 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
MX2013004906A (es) * 2010-11-01 2013-12-06 Genoscience Pharma Nuevos inhibidores especificos de la proteasa ns3 de hcv.

Also Published As

Publication number Publication date
SG11201608587QA (en) 2016-11-29
IL248318A0 (en) 2016-11-30
RU2016144076A (ru) 2018-05-16
CA2945514A1 (en) 2015-10-22
JP2017513852A (ja) 2017-06-01
WO2015160907A2 (en) 2015-10-22
US20170029407A1 (en) 2017-02-02
EP3131892A2 (en) 2017-02-22
EP3131892A4 (en) 2017-09-20
BR112016023833A2 (pt) 2017-10-10
MX2016013434A (es) 2017-03-03
WO2015160907A3 (en) 2016-12-01
AU2015247706A1 (en) 2016-10-27
PH12016502039A1 (en) 2017-01-09
US9926295B2 (en) 2018-03-27
CN106661004A (zh) 2017-05-10

Similar Documents

Publication Publication Date Title
US9932326B2 (en) Potent and selective inhibitors of hepatitis C virus
US11859014B2 (en) Peptidomimetics for the treatment of Norovirus infection
US9040479B2 (en) HCV NS3 protease inhibitors
RS63714B1 (sr) Jedinjenja koja sadrže nitril korisna kao antivirusna sredstva za lečenje infekcije koronavirusom
US9926295B2 (en) Potent and selective inhibitors of hepatitis C virus
JP2012504632A (ja) Ｃ型肝炎ウイルス阻害剤
JP5828903B2 (ja) 新規特異的ｈｃｖ ｎｓ３プロテアーゼ阻害剤
US20170037078A1 (en) 2' -disubstituted nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
CA2984421A1 (en) Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000